Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: Drug monitoring and tolerability data from a prospective clinical trial

Pharmacopsychiatry

Volumn 32, Issue 4, 1999, Pages 148-153

  Szegedi, Armin ^a   Anghelescu, I ^b   Wiesner, J ^b   Schlegel, S ^b   Weigmann, H ^b   Hartter S ^b   Hiemke, Ch ^b   Wetzel, H ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUVOXAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0032863283     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979221     Document Type: Article

References (25)

1. 1 Baumann P, Rochat B: Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int. Clin. Psychopharmacology 1995; 10 (Suppl. 1): 15-21
2. 2 Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 1993; 45: 1211-1214
3. 3 Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry 1996; 153: 820-822
4. 4 Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Flood JG: Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J. Clin. Psychopharmacol. 1994; 14: 119-125
5. 5 Freudenreich O, Weiner RD, McEvoy JP: Clozapine-induced electro-encephalogram changes as a function of clozapine serum levels. Biol. Psychiat. 1997; 42: 132-137
6. 6 Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H, Fleischhacker WW: EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology 1994; 114: 97-100
7. 7 Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H. Müller H: Elevated levels of clozapine in serum after addition of fluvoxamine. J. Clin. Psychopharmacol. 1994; 14: 279-281
8. 8 Jerling M, Lindstrom L, Bondesson U, Bertilsson L: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther. Drug Monit. 1994; 16: 368-374
9. 9 Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 1988; 45: 789-796
10. 10 Koponen HJ, Leinonen E, Lepola U: Fluvoxamine increases the clozapine serum levels significantly. European Neuropsychopharmacology 1996; 6: 69-71
11. 11 Lindenmayer J-P, Grochowski S, Mabugat L: Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J. Clin. Psychopharmacol. 1994; 14: 201-204
12. 12 Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. Acta Psychiat. Scand. 1987; 76 (Suppl. 334): 1-100
13. 13 Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry 1995; 152: 183-190
14. 14 Olesen OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen NA, Refshammer C, Sorensen J, Bysted M, Christensen J, Rosenberg R: Clozapine serum levels and side effects during steady-state treatment of schizophrenic patients. Psychopharmacology 1995; 153: 371-378
15. 15 Pacia SV, Devinsky O: Clozapine-related seizures: experience with 5629 patients. Neurology 1994; 44: 2247-2249
16. 16 Sajatovic M, Meltzer HY: Clozapine-induced myoclonus and generalized seizures. Biol. Psychiatry 1996; 39: 367-370
17. 17 Salokangas RKR, Saarjävi S, Taiminen T, et al: Citalopram as an adjuvant in chronic schizophrenia: a double blind placebo controlled study. Acta Psychiatr. Scand. 1996; 94: 175-180
18. 18 Silver H, Kaplan A, Jahjah N: Fluvoxamine augmentation for clozapine-resistant schizophrenia. Am. J. Psychiatry 1995; 152(7): 1098
19. 19 Silver H, Nassar A: Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo controlled study. Biol. Psychiatry 1992; 31: 698-704
20. 20 Siris SG, Bermanzohn PC, Mason SE, Shuwall MA: Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch. Gen. Psychiatry 1994; 51: 109-115
21. 21 Szegedi A, Wiesner J, Hiemke C: Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J. Clin. Psychopharmacol. 1995; 15: 141-143
22. 22 Thakore JH, Berti C, Dinan TG: An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatr. Scand. 1996; 94: 194-197
23. 23 Thulesius O: Pathophysiological classification and diagnosis of orthostatic Hypotension. Cardiology 1976; 61 (Suppl. 1): 180-190
24. 24 Weigmann H, Hiemke C: Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high performance liquid chromatography with ultra violet detection. J. Chromatogr. 1992; 583: 209-216
25. 25 Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Härtter S, Hiemke C: Pharmakokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J. Clin. Psychoparmacol. 1998; 18: 2-9